Author

S. Badloe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:whole-genome sequencing· 2 Research Focus:clustering· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. Janse· 2 shared J. Drost· 2 shared J. Y. Hehir-Kwa· 2 shared M. M. van den Heuvel-Eibrink· 2 shared P. Kemmeren· 2 shared S. de Vos· 2 shared A. Groenendijk· 1 shared B. B. J. Tops· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Janse

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Complex structural variation is prevalent and highly pathogenic in pediatric solid tumors

I. A. E. M. van Belzen, M. C. van Tuil, S. Badloe, A. Janse, E. T. P. Verwiel, M. Santoso, S. de Vos, J. Baker-Hernandez, H. H. D. Kerstens, N. Solleveld-Westerink, M. T. Meister, J. Drost, M. M. van den Heuvel-Eibrink, J. H. M. Merks, J. J. Molenaar, , J. Y. Hehir-Kwa

The paper identifies prevalent and pathogenic complex structural variations in pediatric solid tumors, linking them to adverse clinical outcomes and potential therapeutic targets.

bioRxiv · Sep 19, 2023Cancer Biology

Molecular characterization reveals subclasses of 1q gain in intermediate-risk Wilms tumors

I. A. van Belzen, M. van Tuil, S. Badloe, E. Strengman, A. Janse, E. T. Verwiel, D. F. van der Leest, S. de Vos, J. L. Baker-Hernandez, A. Groenendijk, R. de Krijger, H. H. Kerstens, J. Drost, M. M. van den Heuvel-Eibrink, B. B. Tops, , J. Y. Hehir-Kwa

The paper identifies subclasses of 1q gain in Wilms tumors by integrating genomic and expression data, revealing differences in mutational mechanisms and functional effects.

bioRxiv · Aug 12, 2022 · PreprintCancer Biology